Illumina Officials Say Array Business Will Benefit from Epicentre Buy | GenomeWeb

By Justin Petrone

Illumina's acquisition of reagent maker Epicentre Biotechnologies could offer some advantages for its microarray business, according to company officials.

CEO Jay Flatley said during an earnings call last week that the firm has in the past licensed "several" Epicentre enzymes for use in its array business. Now the firm has the "ability to use those enzymes at cost rather than [retail] price," he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.